Celgene abandons Crohn's drug trials, shares drop

(Reuters) - Celgene Corp said it would abandon testing a drug to treat Crohn's disease, in a major setback to the U.S. biotechnology company's pipeline amid attempts to lower dependence on its mainstay Revilimid.